Biotechnology patent applications often contain nucleotide, amino acid, peptide, DNA, RNA, or other biological sequence information. Because these sequences can be central to the invention – and can be difficult to search and examine – the Indian Patent Office (IPO India) requires sequence disclosures to be submitted in a prescribed electronic format.
For applications filed today, understanding the relationship between Rule 9 of the Patents Rules, 2003 and WIPO Standard ST.26 is particularly important.
The Key Indian Requirement: Rule 9
Under Rule 9(3) of the Patents Rules, 2003, when a patent application discloses nucleotide or amino acid sequences, the sequence listing must be filed in computer-readable text format along with the application.
Importantly, the current Indian rule states that a print version of the sequence listing is not required.
This means that applicants preparing an Indian biotechnology patent application should not treat the sequence listing as merely an optional formatting exercise. It is a specific filing requirement where the application contains qualifying sequence disclosures.
WIPO ST.26 and Indian Patent Applications
A major development in sequence-listing practice was the transition from WIPO Standard ST.25 to WIPO Standard ST.26.
ST.26 became applicable internationally from July 1, 2022. Applications filed on or after that date that disclose nucleotide or amino acid sequences generally require an ST.26-compliant XML sequence listing.
ST.26 uses XML rather than the older ST.25 sequence-listing format and was designed to provide greater international consistency and better compatibility with sequence databases.
For applicants filing biotechnology patent applications in India, this makes ST.26 compliance an important part of preparing the application package.
Which Sequences Need to Be Included?
One of the most important practical questions is determining which sequences actually need to appear in the listing.
Under ST.26, a disclosed sequence generally needs to be included when it contains:
- 10 or more specifically defined nucleotides, or
- 4 or more specifically defined amino acids
subject to the detailed requirements and exceptions in the Standard.
ST.26 also permits inclusion of certain shorter sequences, but sequences below the applicable thresholds should not simply be assigned sequence identification numbers as though they were mandatory qualifying sequences.
This distinction becomes important in applications containing primers, probes, oligonucleotides, short peptides, fragments, variants, or sequence motifs.
What Information Does an ST.26 Sequence Listing Contain?
An ST.26 sequence listing is more than a text file containing strings of A, T, G, C, or amino-acid symbols.
It uses structured XML data and can contain information associated with each sequence, including sequence identification numbers and relevant sequence characteristics.
The sequence listing also contains prescribed bibliographic information. WIPO guidance, for example, addresses information such as the applicant, invention title, application information and priority information where applicable.
The exact data structure should be generated and validated using the applicable ST.26 tools rather than manually constructing the XML.
Use WIPO Sequence to Prepare the Listing
WIPO provides WIPO Sequence, a dedicated desktop application for preparing ST.26-compliant sequence listings.
The software is available for Windows, Linux and macOS and is specifically designed to help applicants create compliant sequence listings. WIPO also provides a validator for checking ST.26 files.
For a biotech patent filing, a practical workflow is:
- Identify all nucleotide and amino acid sequences disclosed in the specification.
- Determine which sequences fall within the ST.26 requirements.
- Assign appropriate sequence identification numbers.
- Enter the sequence information into WIPO Sequence.
- Add the required bibliographic and sequence-related information.
- Validate the resulting XML file.
- Review the listing against the patent specification and claims.
- File the sequence listing electronically with the Indian patent application.
Why Accuracy Between the Specification and Sequence Listing Matters
One of the most important considerations is consistency.
The sequence listing should accurately correspond to the disclosure in the patent application. Applicants should carefully check:
- Sequence identification numbers
- Nucleotide sequences
- Amino acid sequences
- Sequence orientation
- Translation information
- Variants and substitutions
- Ambiguous residues
- Sequence annotations
- References to sequences throughout the specification and claims
An error in a sequence listing can create unnecessary prosecution complications, particularly where the sequence is important to the claimed invention.
More importantly, adding new technical information after filing can raise added-matter or new-matter concerns. WIPO’s ST.26 guidance specifically notes that sequence listings submitted after filing must be considered in light of whether the information could constitute added subject matter.
Sequence Listings and Patent Examination
Sequence listings are valuable to patent examiners because biological sequence information can be searched computationally.
IPO India’s biotechnology examination guidance states that examiners may use sequence-based search approaches and databases, including tools such as BLAST and FASTA, as part of prior-art searching. IIP India
Consequently, sequence formatting is not merely an administrative requirement.
A properly prepared sequence listing can facilitate examination of questions involving:
- Novelty
- Inventive step
- Sequence identity
- Sequence similarity
- Biological function
- Prior-art disclosures
- Relationships between claimed and known sequences
ST.25 vs. ST.26: Why the Transition Matters
Applicants familiar with older Indian patent filings may encounter ST.25 sequence listings in earlier applications.
The transition date is important.
WIPO’s implementation guidance states that the filing date, rather than the priority date, is the relevant reference point for determining whether ST.25 or ST.26 applies to the application. Applications filed on or after July 1, 2022 generally require ST.26, while applications filed before that date continue to be governed by ST.25 for their sequence-listing requirements.
Therefore, simply converting an older ST.25 listing to ST.26 is not necessarily the correct approach in every prosecution or national-phase situation.
The application history and applicable filing requirements should be reviewed carefully.
Special Considerations for PCT Applications Entering India
Biotechnology applicants frequently use the PCT route before entering the Indian national phase.
For international applications filed on or after July 1, 2022, WIPO requires sequence listings to comply with ST.26. WIPO’s PCT guidance states that sequence listings must be submitted in XML format and that applications containing qualifying sequences without the required listing can become defective or create difficulties later.
Accordingly, applicants preparing an Indian national-phase filing should carefully verify that the sequence listing accompanying the PCT application and the material submitted for Indian prosecution are consistent with the applicable requirements.
Common Mistakes in Indian Biotech Sequence Listings
Several errors can complicate prosecution.
1. Using the wrong sequence-listing standard
Using an old ST.25 format for an application to which ST.26 applies can create compliance issues.
2. Missing qualifying sequences
Applicants sometimes identify only the sequences appearing in the claims while overlooking sequences disclosed elsewhere in the specification.
The listing should be prepared by reviewing the entire disclosure, not merely the claims.
3. Inconsistent sequence numbering
A sequence referred to as SEQ ID NO: 5 in the specification should correspond to the same sequence in the electronic listing.
4. Manually editing the XML
Manual modification of a generated sequence listing can introduce formatting or validation errors.
Using WIPO Sequence and validating the final file is generally safer.
5. Introducing new sequences after filing
Adding sequences that were not adequately disclosed in the original application can raise substantive patent-law issues, not merely formatting issues.
6. Ignoring sequence variants
Biotechnology inventions frequently involve variants, mutants, homologues, consensus sequences, or sequences containing ambiguous positions. These require careful analysis under ST.26 rather than simplistic copying of the sequence text.
A Practical Compliance Checklist
Before filing an Indian biotechnology patent application containing sequence information, applicants should consider the following checklist:
- Identify: Have all nucleotide and amino acid sequences in the disclosure been identified?
- Classify: Which sequences meet the applicable ST.26 inclusion criteria?
- Prepare: Has the listing been generated in the required XML format?
- Validate: Has the file passed appropriate ST.26 validation?
- Cross-check: Do the sequence IDs correspond exactly with those used in the specification and claims?
- Review: Are variants, ambiguities, annotations and translations represented correctly?
- Confirm: Does the sequence listing contain only information supported by the application disclosure?
- File: Is the computer-readable sequence listing being submitted with the application as required by Rule 9?
Conclusion
Sequence listings are an essential component of many biotechnology patent applications filed before the Indian Patent Office.
For current filings, applicants need to pay particular attention to Rule 9 of the Patents Rules, 2003 and the requirements of WIPO ST.26. The Indian rules require qualifying nucleotide and amino acid sequence listings to be submitted in computer-readable form, while ST.26 provides the international framework for structuring and representing those sequences.
Using a structured workflow – identifying sequences early, preparing the listing with WIPO Sequence, validating the XML and carefully cross-checking it against the patent specification – can help reduce filing errors and prosecution complications.
For biotech companies, universities, research institutions and patent professionals, sequence-listing compliance should therefore be treated as an integral part of patent drafting and filing strategy, rather than as a last-minute technical formality.